
RIMA: Difference between revisions
>David Hedlund Merged "* Harmaline" from the MAOI page |
>David Hedlund {{see also|MAOI#Examples}} |
||
Line 5: | Line 5: | ||
==Examples== | ==Examples== | ||
{{see also|MAOI#Examples}} | |||
* [[Harmaline]] | * [[Harmaline]] | ||
Revision as of 13:43, 6 October 2018
This article is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
Reversible inhibitors of monoamine oxidase A (RIMAs) are a class of drugs which selectively and reversibly inhibit the enzyme monoamine oxidase A (MAO-A). They are used clinically in the treatment of depression and dysthymia, though they have not gained widespread market share due to limited efficacy relative to other antidepressants. Because of their reversibility and selectivity, RIMAs are safer than the older monoamine oxidase inhibitors (MAOIs).[1]
While safer than general MAOIs, RIMAs still have highly dangerous and sometimes fatal interactions with many common drugs; in particular, they can cause serotonin syndrome or hypertensive crisis when combined with almost any antidepressant or stimulant, common migraine medications, certain herbs, or even most cold medicines (including decongestants, antihistamines, and cough syrup).
Examples
Pharmaceuticals
- Moclobemide (commonly known by the trade names Amira, Aurorix, Clobemix , Depnil and Manerix)